Nkarta. has filed a patent for methods and compositions involving engineered immune cells expressing chimeric antigen receptors (CAR) to reduce side effects of cellular immunotherapy. The genetic modifications aim to enhance cytotoxicity and persistence, with a focus on targeting CD70 for renal cell carcinoma treatment. GlobalData’s report on Nkarta gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Nkarta Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Nkarta, Cytokine activate T-cell based compositions was a key innovation area identified from patents. Nkarta's grant share as of January 2024 was 6%. Grant share is based on the ratio of number of grants to total number of patents.

Genetically modified immune cells for safer immunotherapy targeting cd70

Source: United States Patent and Trademark Office (USPTO). Credit: Nkarta Inc

A recently filed patent (Publication Number: US20230390392A1) discloses a series of claims related to an anti-CD70 binding domain, specifically a single-chain variable fragment (scFv) consisting of a variable heavy chain region (VH) and a variable light chain region (VL) linked by a specific amino acid sequence. The patent outlines various configurations of the VH and VL regions, including specific complementarity-determining regions (CDRs) with defined amino acid sequences. Additionally, the patent describes the construction of an anti-CD70 chimeric antigen receptor (CAR) incorporating the binding domain, a transmembrane domain, and a cytotoxic signaling complex. The CAR can further include signaling domains such as OX40, CD28, or 4-1BB for enhanced functionality.

Furthermore, the patent details methods for genetically engineering immune cells, particularly natural killer (NK) cells, to express the anti-CD70 CAR. These engineered NK cells are designed to target CD70-expressing tumors and can be modified to reduce the expression of specific genes like CD70, CISH, and CBLB. The patent also covers compositions comprising these engineered immune cells and methods for treating cancer by administering them to subjects. The process involves expanding immune cells in culture, inducing genomic disruptions using endonucleases and guide RNAs, and transducing the cells with a viral vector encoding the CD70-targeting CAR. This innovative approach aims to enhance the efficacy of immunotherapy for cancer treatment.

To know more about GlobalData’s detailed insights on Nkarta, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies